New combo therapy aims to control advanced colon cancer
NCT ID NCT05985954
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests the safety and best dose of a drug called ulixertinib when given with cetuximab and/or encorafenib. It is for people with advanced colorectal cancer that has spread and who have already tried treatments targeting EGFR or BRAF. The goal is to find a dose that controls the cancer with manageable side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?